Navigation Links
Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23

his cautionary statement and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    CONTACTS:

    OREXIGEN                    MEDIA                    INVESTORS

    Graham Cooper               Stephen Gendel           Jason Spark

    858 436-8600                212 918-4650             619 849-6005

CONTACT: Graham Cooper, +1-858-436-8600, Stephen Gendel, +1-212-918-4650Jason Spark, +1-619-849-6005, all for Orexigen(TM) Therapeutics, Inc.

Web site: http://www.Orexigen.com/

Ticker Symbol: (NASDAQ-NMS:OREX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Post Your Comments:
(Date:8/21/2008)... Aug. 21 /-,Bayer HealthCar...Inc.,(Nasdaq: ONXX ) today announced the companie...enib as Adjuvant Treatment in the Prevention of,Re...ndomized, double-blind,placebo-controlled Phase 3...s as adjuvant treatment, which is treatment follow...
(Date:8/20/2008)...nobia Pharma, an emerging biotech,company focused ...disorders, today announced that the first patient ...een dosed. Enobia is investigating Enzyme,Replacem...of this rare and,often crippling genetic bone diso...nder two separate protocols, ENB-0040 will be eval...
(Date:8/19/2008)...-,Pharmaceutical company Ph...hat the Phase 3 clinical trial evaluating the long...iectasis has concluded with no serious,adverse eve...treatment., A total of 123 subjects started treat...ubjects completed the full 12 months of the trial....
(Date:8/19/2008)...be used to identify molecular,signature of motor n...ire-USNewswire/ -- ALS Therapy,Development Institu...n ALS,biomarker effort using blood samples collect...ships. These ongoing projects are part of the,Inst...expression of genes,and proteins, at the onset of,...
Breaking Medicine Technology:Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 2Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 3Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 4Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 5Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 2Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 312 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 212 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 3ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Researchers discover natural herbicide released by grass 1144 1Researchers discover natural herbicide released by grass 1144 2St Jude program reduces weight gain in young African American girls 5856 1St Jude program reduces weight gain in young African American girls 5856 2Skin Cancer Prevention Update 3A 5853 1Skin Cancer Prevention Update 3A 5853 2Skin Cancer Prevention Update 3A 5853 3Skin Cancer Prevention Update 3A 5853 4Skin Cancer Prevention Update 3A 5853 5Feeling Stressed 3F 5850 1Feeling Stressed 3F 5850 2Feeling Stressed 3F 5850 3Feeling Stressed 3F 5850 4
...ased Enzyme Levels in Two Most Common Mutations, C...us,Therapeutics, a biopharmaceutical company devel...logical chaperones for the,treatment of a range of...ill present the results of preclinical studies of,...cher disease at,the of Medical Genetics (ACMG) ann...
...clinical Studies Presented at the Targeted,Antican... Molecular,Targets for Cancer Meetings Support Pha...rch 20, 2007,/PRNewswire-FirstCall/ -- Sunesis Pha...n its development-stage compound, SNS-314, at,two ...ticancer,medicines. Findings from in vitro and in ...
Other Medicine Technology:Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 2Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 3
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...ing system for use by physicians predicts early ri...ransient ischemic attack, known as TIA and also ca...out 240,000 TIAs are diagnosed every year in the U...United Kingdom. A TIA is a serious condition cause...
...nase (ADH) is one of the major enzymes involved in...phic at two loci, ADH1B and ADH1C.// The three al...ed with protection from alcohol dependence, a new ...tionship between the ADH1B*3 allele and alcohol-re...
...global acquisitions last year, India's Ranbaxy Lab...the generic drugs business of German// pharmaceuti...llion. ‘We are in talks with private equity funds... executive Malvinder Singh said on the margins of ...
...ochrane Review concluded antidepressants bupropion...es //of giving up smoking and have few side-effect...RIs) such as fluoxetine (Prozac) are not effective...own to help people quit smoking, not everyone is h...
Other Medicine News:Health News:New Tool Improves Prediction of Stroke Risk 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 3
Inquire
...yles. Each style has multiple sizes. Style 1 is by... available non-sterile and sterile, and are packag...s are mirror-image meaning that they are each made... normally inserted through a transaxillary (armpit...
...vivo results may be affected by the thickness of t...on scar tissue can impact the desired augment-atio...from patient to patient. Implant dimensions can be... scissors. All dimensions in centimeters. This dev...
...Qmark family elevates your ECG and Spirometry capa...ity, cost-savings and efficient patient care. The ...in the office, clinics and medical centers as well...en used in conjunction with the IQmark Digital ECG...
Medicine Products: